Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

CIB1 and CIB2 are HIV-1 helper factors involved in viral entry.

Godinho-Santos A, Hance AJ, Gonçalves J, Mammano F.

Sci Rep. 2016 Aug 4;6:30927. doi: 10.1038/srep30927.

2.

Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Méndez C, Ahlenstiel CL, Kelleher AD.

World J Virol. 2015 Aug 12;4(3):219-44. doi: 10.5501/wjv.v4.i3.219. Review.

3.

CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.

Hütter G, Bodor J, Ledger S, Boyd M, Millington M, Tsie M, Symonds G.

Viruses. 2015 Jul 27;7(8):4186-203. doi: 10.3390/v7082816. Review.

4.

RNA interference approaches for treatment of HIV-1 infection.

Bobbin ML, Burnett JC, Rossi JJ.

Genome Med. 2015 May 28;7(1):50. doi: 10.1186/s13073-015-0174-y. eCollection 2015.

5.

Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants.

Eszterhas SK, Ilonzo NO, Crozier JE, Celaj S, Howell AL.

Infect Dis Rep. 2011 Sep 7;3(2):e11. doi: 10.4081/idr.2011.e11. eCollection 2011 Sep 7. Review.

6.

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A.

Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467.

7.

Closing the door to human immunodeficiency virus.

Kang Y, Guo J, Chen Z.

Protein Cell. 2013 Feb;4(2):86-102. doi: 10.1007/s13238-012-2111-9. Epub 2013 Mar 12. Review.

8.

Inhibition of human immunodeficiency virus replication by cell membrane-crossing oligomers.

Posch W, Piper S, Lindhorst T, Werner B, Fletcher A, Bock H, Lass-Flörl C, Stoiber H, Wilflingseder D.

Mol Med. 2012 Feb 10;18:111-22. doi: 10.2119/molmed.2011.00128.

9.

Epigenetic diet: impact on the epigenome and cancer.

Hardy TM, Tollefsbol TO.

Epigenomics. 2011 Aug;3(4):503-18. doi: 10.2217/epi.11.71. Review.

10.

Delivery systems for in vivo use of nucleic Acid drugs.

Resende RR, Torres HA, Yuahasi KK, P M, H U.

Drug Target Insights. 2007;2:183-96. Epub 2007 Aug 9.

11.

HIV-1 RT-dependent DNAzyme expression inhibits HIV-1 replication without the emergence of escape viruses.

Sugiyama R, Hayafune M, Habu Y, Yamamoto N, Takaku H.

Nucleic Acids Res. 2011 Jan;39(2):589-98. doi: 10.1093/nar/gkq794. Epub 2010 Sep 9.

12.

Possible applications for replicating HIV 1 vectors.

Das AT, Jeeninga RE, Berkhout B.

HIV Ther. 2010 May 1;4(3):361-369.

13.

A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N, Kittipongdaja P, Chen A, Bristol G, Galic Z, Zack JA, Yang O, Chen IS, Lee B, An DS.

Blood. 2010 Feb 25;115(8):1534-44. doi: 10.1182/blood-2009-04-215855. Epub 2009 Dec 17.

14.

Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.

Anderson JS, Javien J, Nolta JA, Bauer G.

Mol Ther. 2009 Dec;17(12):2103-14. doi: 10.1038/mt.2009.187. Epub 2009 Aug 18.

15.

Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.

Anderson JS, Walker J, Nolta JA, Bauer G.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):152-61. doi: 10.1097/QAI.0b013e3181b010a0.

16.

Lipid-based systemic delivery of siRNA.

Tseng YC, Mozumdar S, Huang L.

Adv Drug Deliv Rev. 2009 Jul 25;61(9):721-31. doi: 10.1016/j.addr.2009.03.003. Epub 2009 Mar 26. Review.

17.

Emergence of a complex relationship between HIV-1 and the microRNA pathway.

Ouellet DL, Plante I, Barat C, Tremblay MJ, Provost P.

Methods Mol Biol. 2009;487:415-33. doi: 10.1007/978-1-60327-547-7_20. Review.

18.

Chemokines as therapeutic targets in renal cell carcinoma.

Reckamp KL, Strieter RM, Figlin RA.

Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93. doi: 10.1586/14737140.8.6.887. Review.

19.

Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron.

Liu YP, Haasnoot J, ter Brake O, Berkhout B, Konstantinova P.

Nucleic Acids Res. 2008 May;36(9):2811-24. doi: 10.1093/nar/gkn109. Epub 2008 Mar 16.

20.
Items per page

Supplemental Content

Write to the Help Desk